BEGIN:VCALENDAR VERSION:2.0 CALSCALE:GREGORIAN PRODID:iCalendar-Ruby BEGIN:VEVENT CATEGORIES:Lectures & Presentations DESCRIPTION:MCB Seminar | Benefits and Drawbacks of Drug Combinations in Ca ncer Treatment\, March 30\n\nThe Molecular and Cellular Biology Seminar ser ies features Emily Davis discussing "The Benefits and Drawbacks of Drug Com binations in Cancer Treatment" on March 30 from 4:35 to 5:55 p.m.\n\nContac t Dr. Sarah Wyatt\, MCB director\, for Teams information.Davis is a graduat e student in Biological Sciences at Ohio University and a member of the Mol ecular and Cellular Biology program.\n\nAbstract: Combinations of individua lly active therapeutic agents\, referred to as drug cocktails\, are frequen tly used in clinical settings to amplify the patient’s response to therapy and diminish the likelihood of acquiring resistance to therapy.1 Drug cock tails can increase the efficacy of cancer treatment while allowing lower do ses of each individual drug to be used\, thereby reducing toxicity.1\,2 How ever\, in approximately 66% of drug cocktails\, the therapeutic benefit to the patient is only equivalent to that of the single most effective drug in the cocktail. In the remaining 33% of cases\, the drugs in the cocktail wo rk synergistically to significantly increase the therapeutic benefit to the patient and improve their prognosis.1 Gao\, et. al\, have identified one s uch drug cocktail\, consisting of a chemotherapy drug\, an anti-cerebral va sospasm drug\, and an anti-allergy drug. They designed this cocktail to tre at glioblastoma multiforme (GBM)\, which is the most common and most aggres sive brain tumor in adults. To ensure that all three drugs were necessary t o exhibit the cocktail’s synergistic effects\, Gao\, et. al tested each dru g individually\, as well as all possible combinations of two drugs\, and fo und that nothing produced as significant of a beneficial effect as the full cocktail. In both in vitro and patient-derived xenograft mouse models\, th eir cocktail effectively reprogrammed GBM cells into neuronal cells.3 Syne rgistic drug cocktails\, such as the one developed by Gao\, et. al\, will l ikely play a significant role in the immediate future of cancer treatments\ , as the development of new drugs is both time-consuming and costly.\n\nKey References\n\nPalmer\, A.C.\, Sorger\, P.K. (2017). Combination Cancer The rapy Can Confer Benefit via Patient-to-Patient Variability Without Drug Add itivity or Synergy. Cell 171\, 1678-1691. Wang\, H.\, et. al (2020). Bioma terial-based scaffold for in situ chemo-immunotherapy to treat poorly-immun ogenic tumors. Nature Communications 11\, 5696. Gao\, L.\, et. al (2019). S uppression of glioblastoma by a drug cocktail reprogramming tumor cells int o neuronal-like cells. Scientific Reports 9\, 3462. DTEND:20210330T215500Z DTSTAMP:20241124T075844Z DTSTART:20210330T203500Z LOCATION: SEQUENCE:0 SUMMARY:MCB Seminar | Benefits and Drawbacks of Drug Combinations in Cancer Treatment\, March 30 UID:tag:localist.com\,2008:EventInstance_36209680655845 URL:https://calendar.ohio.edu/event/mcb_seminar_emily_davis_on_march_30 END:VEVENT END:VCALENDAR